| Unit Size | Price | Quantity |
|---|---|---|
| 10mL | $493.00 | |
| 100mL | $2,064.00 |
BangsLaboratories位于美国印地安那州，成立于1988年，专业生产生命科学研究用的各种微球达2000种以上，用于流式细胞分析，生物大分子的分离与检测，激光共聚焦，生物影像等。BangsLaboratories于2000年收购了成立于1984年的流式标准品公司，该公司掌握了许多标准品和校正品的专利。Bangs产品通过与流式细胞仪及试剂厂家的OEM合作，进入世界各地实验室。BangsLaboratories的流式分部前称为流式标准品公司，成立于1984年。目前为止，公司自己研发了许多标准品和校正品，并获得美国和其他国家的专利保护。公司的荧光标准品可帮助科研和临床工作人员在实验时更容易更准确地评估数据。公司提供下列领域的质控可定量标准品：流式、荧光显微镜、屏象分析（imageanalysis）以及其它荧光分析。
Bangslabs（BangsLaboratories,Inc.）是高品质特种微球供应商，其产品广泛用于诊断试剂、免疫分析、分子及细胞生物学、流式检测应用等，产品种类已达2000余种，并且逐年递增，完善的技术支持体系为客户提供全方位的项目服务。 热销产品有羧基荧光微球、铕螯合微球、分离磁珠、标准微球、CD抗原标记微球等，适用于时间分辨荧光检测、免疫层析或比浊、细胞及遗传物质分离纯化等科研及工业应用。
BangsLaboratories公司位于美国印地安那州，成立于1988年4月。专业提供生命科学研究用的各种微球。其种类齐全(2000种以上)，可用于流式细胞仪检测,细胞与生物大分子的分离与检测,电镜、共聚焦成像仪、荧光显微镜与相差显微镜的观察等。微球除聚苯乙烯外，还有聚甲基丙烯酸酯，聚乙烯甲苯和硅等多种材料，部分提供羧基或氨基修饰，直径大小从20nm-200um不等，均一性高，有很好的热稳定性。公司可提供个性化服务，根据你需要的颜色染色。BangsLaboratories的流式分部前称为流式标准品公司，成立于1984年。目前为止，公司自己研发了许多标准品和校正品，并获得美国和其他国家的专利保护。Bangs作为流式定量领域的领导者，产品已进入世界各地。公司的荧光标准品可帮助科研和临床工作人员在实验时更容易更准确地评估数据。公司提供下列领域的质控可定量标准品：流式、荧光显微镜、屏象分析(imageanalysis)以及其它荧光分析。QuantumTMplex在流式细胞仪的基础上，实现多样品检测或多指标检测，用于细胞因子检测、病毒筛选、自免疫分析、抗体检测、药物、血型、分子诊断以及基因组分析等。使用本试剂盒可在流式细胞仪上对一个样品同时检测20个不同指标(如不同细胞因子或不同抗原)。QuantumPlex?SP微球同样是研究者理想的选择，由于它是以QuantumPlexmultiplex试剂盒内的StarfireRed染料染色，研究者可以在花费不多的情况下处理表面偶联物。QuantumTMMESFKits用于流式细胞仪的标准曲线制作与仪器校正，与QuantumTMplex配套。试剂盒中的每种微球均对应溶液中一定量的荧光分子，用于流式细胞仪的荧光强度校正。试剂盒内除了荧光标准品外，还有一个未染色的微球population以测定荧光阈值或设备的噪音水平。盒内提供QuickCal数据光盘。QuantumTMSimplyCellular®kit本试剂盒是BangsLabs最复杂产品之一，用于流式实验室可直接而简单地定量检测细胞的抗体结合能力和细胞表面的抗原表达。盒内有五种微球，一个为未标记的空白对照，其余四个与不同量人IgGI和IgGII抗体的Fc区特异性抗体偶联，分别具有不同的与小鼠IgG单抗结合的能力。QC3TMkit&QC3Windows®kitQC3kit用于监控与校正仪器的设置及性能，使不同实验室间流式细胞仪的检测结果具有可比性，避免因为污染或pH改变造成的偏差；QC3Windows?kit含有3种不同荧光的QC3微球与一种空白微球。QuickCalTMv.2.1用于BangsLabs公司所有Quantum产品的检测结果的分析。该软件适用于所有的流式细胞仪软件可根据MESF微球的荧光强度等建立标准曲线。该软件还可保存仪器设置，使仪器的性能得到长期有效保证。ProActiveTMProtein-activatedorProtein-CoatedMicrospheres采用独有的包被技术偶联生物素、DNA、HRP/AP以及抗体等，确保包被微球更稳定、包被效果更好。用于免疫学和分子生物学检测 Superparamagnetic磁珠Superparamagnetic磁珠表面可高效共价交联蛋白质或DNA等，被广泛应用于诊断与其它生命科学研究。COMPEL?磁珠适用于各种生物学检测与分离，有3、6和8um等几种直径，磁珠受强磁性吸引，使其与溶液的分离极为方便，同时残余磁性极低，是生命科学研究的理想选择。磁珠分离器MagneticSeparatorsBangsLaboratories公司1.5mL磁珠分离器用于各种不同的磁珠分离实验中，包括细胞分选、mRNA与DNA分离与其它生物大分子的纯化等。使用时，只要将装有磁珠的离心管放入分离器中，仪器就能产生高能磁场使磁珠得以与溶液分离开，从而实现磁珠的分离。此外，BangsLaboratories公司提供各种微球标准，如不同直径、不同荧光的荧光强度；硅微球UniformSilicaMicrospheres除各种分子生物学与免疫学检测用途外，还可用于毛细管电色谱分析(capillaryelectrochromatography，CEC)
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
名称：氨氧基乙酸盐;羧甲氧基胺半盐酸盐；
分子式：C2H5NO3·0.5HCl
分子质量：109.30
熔点：156℃
【认领须知】
1、认领翻译的战友请跟帖注明“认领本文翻译，48小时内未完成，请其他战友认领！”
2、请根据自己专业背景选择认领，如使用翻译软件翻译，被发现者扣分1-2分
3、经常认领而不能及时提供优质稿件者将被列入黑名单，取消认领资格，请大家注意！
4、翻译时请参照版规：点击查看互
5、在首位认领战友未超过规定时间的其他任何认领属违规认领，将不会给予丁当或加分！
6、翻译完成后加分（或丁当）的时限为三日，请耐心等待，若超过时限未加者可进行申诉：点击进入
7、本文题目仅供译者参考，篇幅较长者可申请适当延时
8、翻译前请查一下有无重复帖
9、为保证翻译质量，每人每天最多只能认领两篇
10、链接：http://www.ascopost.com/News/57763
ICML2017:PhaseIIIbMAGNIFYStudyofLenalidomideandRituximabCombinationinRelapsed/RefractoryFollicularandMarginalZoneLymphoma
AninterimanalysisofMAGNIFY,aphaseIIIb,randomized,open-label,multicenterstudyoftheR2combinationregimen(lenalidomide[Revlimid]plusrituximab[Rituxan])inpatientswithrelapsedorrefractorymarginalzonelymphoma,waspresentedattheInternationalConferenceonMalignantLymphoma(ICML)inLugano,Switzerland.ThisanalysisexpandedupondatapresentedearlierinthemonthattheASCOAnnualMeeting(Abstract7502).
TheMAGNIFYstudycontinuestoevaluatetheclinicalactivityof12cyclesofR2combinationtherapyfollowedbyrandomizationtoeither18cyclesofR2maintenanceor18cyclesofrituximabmonotherapy,inpatientswithrelapsedorrefractoryfollicularlymphoma,marginalzonelymphoma,ormantlecelllymphoma.Approximately500patientsareplannedtobeenrolledinthestudy.
Theprimaryendpointisprogression-freesurvival.Secondaryendpointsincludeoverallsurvival,overallresponserate,completeresponse,improvementofresponse,durationofresponse,durationofcompleteresponse,timetonextlymphomatreatment,timetohistologictransformation,safety,andexploratoryquality-of-lifemeasures.EnrollmentintheMAGNIFYstudyisongoing.
ASCOData
AttheASCOAnnualMeeting,interimdatawerepresentedfromananalysisofasubsetofpatientsfromtheMAGNIFYstudywithrelapsedorrefractoryfollicularlymphoma(n=160)withearly-relapse(n=52)anddouble-refractory(n=50)disease.
AttheJanuary9,2017,datacutoff,the1-yearprogression-freesurvivalforallfollicularlymphomapatientswas70%,with65%fordouble-refractorypatientsand49%forearly-relapsepatients.Additionally,evaluablefollicularlymphomapatients(n=128)hadanoverallresponserateof66%withacompleteresponse/completeresponse–unconfirmedrateof38%.Fordouble-refractorypatients(n=42),overallresponseratewas45%withacompleteresponse/completeresponse–unconfirmedrateof21%andforearly-relapsepatients(n=43),overallresponseratewas47%withacompleteresponse/completeresponse–unconfirmedrateof21%.Mediandurationofresponsewasnotmetatamedianfollow-upof10.2months.
Themostcommongrade3or4adverseeventsobservedinthestudyforallfollicularlymphoma,double-refractory,andearly-relapsepatients,respectively,wereneutropenia(29%,42%,37%),fatigue(6%,4%,8%),leukopenia(5%,8%,10%),thrombocytopenia(4%,8%,4%),andlymphopenia(3%,6%,4%).
ICMLData
DatapresentedatICMLinaseparateanalysisfocusedonpatientswithmarginalzonelymphoma(n=38),includingnodalmarginalzonelymphoma(n=18),splenicmarginalzonelymphoma(n=10),andmucosa-associatedlymphoidtissuelymphoma(n=10).
Atamedianfollow-upof13.8monthsfrominitiationoftherapywiththeR2combination,evaluablepatientswithmarginalzonelymphoma(n=32)achievedanoverallresponserateof66%withacompleteresponse/completeresponse–unconfirmedrateof44%.Evaluablenodalmarginalzonelymphomapatients(n=14)hadanoverallresponserateof57%withacompleteresponse/completeresponse–unconfirmedrateof57%.Evaluablesplenicmarginalzonelymphomapatients(n=8)hadanoverallresponserateof63%withacompleteresponserateof25%;andevaluablemucosa-associatedlymphoidtissuelymphomapatients(n=10)hadanoverallresponserateof80%withacompleteresponse/completeresponse–unconfirmedrateof40%.Mediandurationofresponsewasnotreachedforanygroup.
Themostcommongrade3or4adverseeventsobservedinpatientswithmarginalzonelymphomawereneutropenia(32%),thrombocytopenia(16%),andleukopenia(11%).
“Thechemotherapy-freecombinationoflenalidomideandrituximab,withcomplementarymechanismsofactionthatarethoughttoenhanceantibodydependentcellularcytotoxicity,continuestoshowencouragingactivityandatolerablesafetyprofileinindolentlymphomas,andparticularlyindifficult-to-treatpatientsubsets,”saidDavidJ.Andorsky,MD,co–principalinvestigatorofthestudyandmedicaloncologistattheRockyMountainCancerCentersinBoulder,Colorado.“Theseresultsinpatientswhohadfailedmultipletherapiesorrelapsedearly,aswellastheactivityinmarginalzonepatientsmeritfurtherstudyinthisareaofindolentlymphoma.”
AboutMAGNIFY
MAGNIFYisaphaseIIIb,multicenter,open-labelstudyofpatientswithgrades1–3bortransformedfollicularlymphoma,marginalzonelymphoma,ormantlecelllymphomawhoreceivedatleast1priortherapyandhadstageI–IV,measurabledisease.Approximately500patientsareplannedforenrollmentin12cyclesofR2induction,withaprojected314patientswithatleaststablediseaseafterinductionrandomized(1:1)to2maintenancearms.
Inductionincludesorallenalidomideat20mg/d,days1–21per28-daycycle(d1–21/28)plusintravenousrituximabat375mg/m2,days1,8,15,and22ofcycle1andday1ofcycles3,5,7,9,and11(28-daycycles).Patientsarethenrandomizedtomaintenancelenalidomideat10mg/d,days1to21/28,cycles13to30,plusrituximabat375mg/m2,day1ofcycles13,15,17,19,21,23,25,27,and29(R2,armA),orrituximabalone(sameschedule,armB).PatientsreceivingR2maintenanceafter18cyclesmaycontinuemaintenancelenalidomidemonotherapyat10mg/d,days1–21/28(perpatientand/orinvestigatordiscretion),untildiseaseprogressionastolerated.Patientswillbefollowedfor≥5yearsafterthelastpatientinitiatesinductiontherapy.
【认领须知】
1、认领翻译的战友请跟帖注明“认领本文翻译，48小时内未完成，请其他战友认领！”
2、请根据自己专业背景选择认领，如使用翻译软件翻译，被发现者扣分1-2分
3、经常认领而不能及时提供优质稿件者将被列入黑名单，取消认领资格，请大家注意！
4、翻译时请参照版规：点击查看
5、在首位认领战友未超过规定时间的其他任何认领属违规认领，将不会给予丁当或加分！
6、翻译完成后加分（或丁当）的时限为三日，请耐心等待，若超过时限未加者可进行申诉：点击进入
7、本文题目仅供译者参考，篇幅较长者可申请适当延时
8、翻译前请查一下有无重复帖
9、为保证翻译质量，每人每天最多只能认领两篇
10、链接:http://www.ascopost.com/News/48387
FDAApprovesLenalidomideasMaintenanceTherapyforPatientsWithMultipleMyelomaFollowingAutologousStemCellTransplant
OnFebruary22,theU.S.FoodandDrugAdmiNISTration(FDA)expandedtheexistingindicationforlenalidomide(Revlimid)10mgcapsulestoincludeuseforpatientswithmultiplemyelomaasmaintenancetherapyfollowingautologoushematopoieticstemcelltransplant.TheexpandedindicationmakeslenalidomidethefirstandonlytreatmenttoreceiveFDAapprovalformaintenanceusefollowingautologoushematopoieticstemcelltransplant.
“Autologousstemcelltransplantafterinductiontherapyispartofthecontinuumofcarefortransplant-eligIBLe[patientswith]multiplemyeloma.However,mostpatientswillstillseetheirdiseaserecurorprogressafterthistreatment,”saidPhilipMcCarthy,MD,Director,BloodandMarrowTransplantCenter,DepartmentofMedicineatRoswellParkCancerInstitute.“Lenalidomidemaintenancetherapy,whichhasbeenshowntoincreaseprogression-freesurvivalfollowingautologousstemcelltransplantinclinicaltrials,canbeconsideredastandardofcareforthesepatients.”
ClinicalTrialFindings
Theapprovalwasbasedontwolargestudies—CALGB100104andIFM2005-02—includingmorethan1,000patientscomparinglenalidomidemaintenancetherapygivenuntildiseaseprogressionorunacceptabletoxicityafterautologoushematopoieticstemcelltransplantvsnomaintenance.Inbothstudies,theprimaryefficacyendpointwasprogression-freesurvival.
Inthemostcurrentprogression-freesurvivalanalysis,Study1(CALGB100104)demonstratedamedianprogression-freesurvivalof5.7years(95%confidenceinterval[CI]=4.4–notestimable)vs1.9years(95%CI=1.6–2.5)fornomaintenance,adifferenceof3.8years(hazardratio[HR]=0.38;95%CI=0.28–0.50).
Study2(IFM2005-02)alsoshowedabenefitwithamedianprogression-freesurvivalof3.9years(95%CI=3.3–4.7)vs2years(95%CI=1.8–2.3)fornomaintenance,adifferenceof1.9years(HR=0.53;95%CI=0.44–0.64).
Individualstudieswerenotpoweredforanoverallsurvivalendpoint.
AdescriptiveanalysisshowedthemedianoverallsurvivalinStudy1was9.3years(95%CI=8.5–notestimable)forpatientswhoreceivedlenalidomidevs7years(95%CI=5.9–8.6)fornomaintenance(HR=0.59;95%CI=0.4–0.78).InStudy2,medianoverallsurvivalwas8.8years(95%CI=7.4–notestimable)forpatientswhoreceivedlenalidomidevs7.3years(95%CI=6.7–9.0)fornomaintenance(HR=0.90;95%CI=0.72–1.13).
AdverseEvents
Themostfrequentlyreportedadversereactionsin≥20%(lenalidomidearm)acrossbothmaintenancestudies(Study1,Study2respectively)wereneutropenia(79%,61%);thrombocytopenia(72%,24%);leukopenia(23%,32%);anemia(21%,9%);upperrespiratorytractinfection(27%,11%);bronchitis(5%,47%);nasopharyngitis(2%,35%);cough(10%,27%);gastroenteritis(0%,23%);diarrhea(55%,39%);rash(32%,8%);fatigue(23%,11%);asthenia(0%,30%);musclespasm(0%,33%);andpyrexia(8%,21%).ThemostfrequentlyreportedGrade3or4reactions(morethan20%inthelenalidomidearm)includedneutropenia,thrombocytopenia,andleukopenia.
Thefrequenciesofonsetofadversereactionsweregenerallyhighestinthefirst6monthsoftreatmentandthenthefrequenciesdecreasedovertimeorremainedstablethroughouttreatment.
Inpatientsreceivinglenalidomidemaintenancetherapy,hematologicsecondprimarymalignanciesoccurredin7.5%ofpatientscomparedto3.3%inpatientsreceivingplacebo.Theincidenceofhematologicplussolidtumor(excludingsquamouscellcarcinomaandbasalcellcarcinoma)secondprimarymalignancieswas14.9%,comparedto8.8%inpatientsreceivingplacebowithamedianfollow-upof91.5months.Nonmelanomaskincancersecondprimarymalignancies,includingsquamouscellcarcinomaandbasalcellcarcinoma,occurredin3.9%ofpatientsreceivinglenalidomidemaintenance,comparedto2.6%intheplaceboarm.
如题，之前买的sigma的粉末，太贵。加培养基又不方便
